miR-378a-3p could bind to the target genes, mitogen-activated protein kinase 1 (MAPK1) and growth factor receptor bound protein 2 (GRB2), leading to the silencing of their expression and reversing the cisplatin resistance of ovarian cancer cells [23]. Here, GRB2 is linked to ovarian carcinoma.